Cardiac mTOR protects the heart against ischemia-reperfusion injury

被引:201
作者
Aoyagi, Toshinori [1 ]
Kusakari, Yoichiro [2 ]
Xiao, Chun-Yang [2 ]
Inouye, Brendan T. [1 ]
Takahashi, Masaya [3 ]
Scherrer-Crosbie, Marielle [4 ]
Rosenzweig, Anthony [2 ]
Hara, Kenta [5 ]
Matsui, Takashi [1 ,2 ]
机构
[1] Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, Honolulu, HI 96813 USA
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Cardiovasc Inst, Boston, MA 02215 USA
[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiol, Boston, MA 02215 USA
[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Ultrasound Lab, Boston, MA USA
[5] Kobe Univ, Kobe, Hyogo 657, Japan
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2012年 / 303卷 / 01期
关键词
myocardial infarction; left ventricular remodeling; transgenic mice; heart failure; MITOCHONDRIAL PERMEABILITY TRANSITION; TUMOR-NECROSIS-FACTOR; MYOCARDIAL-INFARCTION; ISCHEMIA/REPERFUSION INJURY; AKT ACTIVATION; CELL-DEATH; P70S6; KINASE; CARDIOMYOCYTES; MECHANISMS; APOPTOSIS;
D O I
10.1152/ajpheart.00241.2012
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Aoyagi T, Kusakari Y, Xiao C, Inouye BT, Takahashi M, Scherrer-Crosbie M, Rosenzweig A, Hara K, Matsui T. Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 303: H75-H85, 2012. First published May 4, 2012; doi: 10.1152/ajpheart.00241.2012.-Cardiac mammalian target of rapamycin (mTOR) is necessary and sufficient to prevent cardiac dysfunction in pathological hypertrophy. However, the role of cardiac mTOR in heart failure after ischemic injury remains undefined. To address this question, we used transgenic (Tg) mice with cardiac-specific overexpression of mTOR (mTOR-Tg mice) to study ischemia-reperfusion (I/R) injury in two animal models: 1) in vivo I/R injury with transient coronary artery ligation and 2) ex vivo I/R injury in Langendorff-perfused hearts with transient global ischemia. At 28 days after I/R, mortality was lower mTOR-Tg mice than littermate control mice [wild-type (WT) mice]. Echocardiography and MRI demonstrated that global cardiac function in mTOR-Tg mice was preserved, whereas WT mice exhibited significant cardiac dysfunction. Masson's trichrome staining showed that 28 days after I/R, the area of interstitial fibrosis was smaller in mTOR-Tg mice compared with WT mice, suggesting that adverse left ventricular remodeling is inhibited in mTOR-Tg mice. In the ex vivo I/R model, mTOR-Tg hearts demonstrated improved functional recovery compared with WT hearts. Perfusion with Evans blue after ex vivo I/R yielded less staining in mTOR-Tg hearts than WT hearts, indicating that mTOR overexpression inhibited necrosis during I/R injury. Expression of proinflammatory cytokines, including IL-6 and TNF-alpha, in mTOR-Tg hearts was lower than in WT hearts. Consistent with this, IL-6 in the effluent post-I/R injury was lower in mTOR-Tg hearts than in WT hearts. These findings suggest that cardiac mTOR overexpression in the heart is sufficient to provide substantial cardioprotection against I/R injury and suppress the inflammatory response.
引用
收藏
页码:H75 / H85
页数:11
相关论文
共 45 条
[1]
Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase [J].
Avruch, J. ;
Hara, K. ;
Lin, Y. ;
Liu, M. ;
Long, X. ;
Ortiz-Vega, S. ;
Yonezawa, K. .
ONCOGENE, 2006, 25 (48) :6361-6372
[2]
Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death [J].
Baines, CP ;
Kaiser, RA ;
Purcell, NH ;
Blair, NS ;
Osinska, H ;
Hambleton, MA ;
Brunskill, EW ;
Sayen, MR ;
Gottlieb, RA ;
Dorn, GW ;
Robbins, J ;
Molkentin, JD .
NATURE, 2005, 434 (7033) :658-662
[3]
The Cytoprotective Effects of Tumor Necrosis Factor Are Conveyed Through Tumor Necrosis Factor Receptor-Associated Factor 2 in the Heart [J].
Burchfield, Jana S. ;
Dong, Jian-Wen ;
Sakata, Yasushi ;
Gao, Feng ;
Tzeng, Huei-Ping ;
Topkara, Veli K. ;
Entman, Mark L. ;
Sivasubramanian, Natarajan ;
Mann, Douglas L. .
CIRCULATION-HEART FAILURE, 2010, 3 (01) :157-164
[4]
Beneficial Effects of Mammalian Target of Rapamycin Inhibition on Left Ventricular Remodeling After Myocardial Infarction [J].
Buss, Sebastian J. ;
Muenz, Sebastian ;
Riffel, Johannes H. ;
Malekar, Pratima ;
Hagenmueller, Marco ;
Weiss, Celine S. ;
Bea, Florian ;
Bekeredjian, Raffi ;
Schinke-Braun, Martina ;
Izumo, Seigo ;
Katus, Hugo A. ;
Hardt, Stefan E. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (25) :2435-2446
[5]
Complementary therapeutic effects of dual delivery of insulin-like growth factor-1 and vascular endothelial growth factor by gelatin microspheres in experimental heart failure [J].
Cittadini, Antonio ;
Monti, Maria Gaia ;
Petrillo, Valentina ;
Esposito, Giovanni ;
Imparato, Giorgia ;
Luciani, Alessia ;
Urciuolo, Francesco ;
Bobbio, Emanuele ;
Natale, Carlo F. ;
Sacca, Luigi ;
Netti, Paolo A. .
EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (12) :1264-1274
[6]
Dazert E, 2011, CURR OPIN CELL BIOL
[7]
The immune system and cardiac repair [J].
Frangogiannis, Nikolaos G. .
PHARMACOLOGICAL RESEARCH, 2008, 58 (02) :88-111
[8]
Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion [J].
Gurevitch, J ;
Frolkis, I ;
Yuhas, Y ;
Paz, Y ;
Matsa, M ;
Mohr, R ;
Yakirevich, V .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (01) :247-252
[9]
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action [J].
Hara, K ;
Maruki, Y ;
Long, XM ;
Yoshino, K ;
Oshiro, N ;
Hidayat, S ;
Tokunaga, C ;
Avruch, J ;
Yonezawa, K .
CELL, 2002, 110 (02) :177-189
[10]
Restraining PI3K: mTOR signalling goes back to the membrane [J].
Harrington, LS ;
Findlay, GM ;
Lamb, RF .
TRENDS IN BIOCHEMICAL SCIENCES, 2005, 30 (01) :35-42